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Abstract
Background: To identify disease-specific factors associated with cardiovascular events in patients with Takayasu
arteritis (TAK).
Methods: Patients with TAK who fulfilled the American College of Rheumatology 1990 criteria for the classification
of TAK and were followed up between 2006 and 2019 were included. Traditional cardiovascular risk factors and TAK
disease-specific factors at the index date and incident cardiovascular events during the follow-up were
retrospectively assessed. To estimate the risk of cardiovascular events according to TAK disease-specific factors, Cox
regression analysis with adjustment for traditional cardiovascular risk factors was performed.
Results: Of the total 207 patients with TAK, cardiovascular events occurred in 41 (19.8%) patients. Compared with
patients who did not develop cardiovascular events, patients who developed cardiovascular events were older
(38.5 ± 13.4 years vs. 43.6 ± 11.8 years, p = 0.028), more commonly had diabetes mellitus (6.6% vs. 19.5%, p = 0.029),
had lower high-density lipoprotein cholesterol (57.3 ± 17.1 mg/dl vs. 51.2 ± 15.7 mg/dl, p = 0.040), more commonly
had type V vascular involvement (33.1% vs. 63.4%, p 0.001), and less commonly received methotrexate (65.1% vs.
43.9%, p = 0.013). In Cox regression analysis, type V vascular involvement was significantly associated with increased
risk of cardiovascular events (adjusted HR 2.852, 95% CI 1.474–5.518, p = 0.002), whereas the use of methotrexate
was associated with reduced risk of cardiovascular events (adjusted HR 0.515, 95% CI 0.268–0.993, p = 0.047).
Conclusion: Type V vascular involvement was associated with increased risk of cardiovascular events, while the use
of methotrexate was associated with reduced risk of cardiovascular events, in patients with TAK.
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Background
Takayasu arteritis (TAK) is a chronic inflammatory
disease that mainly involves the aorta and its major
branches [1]. Previous studies reported higher preva-
lence of traditional cardiovascular risk factors in patients
with TAK than in healthy controls [2–4]. Moreover, ac-
celerated atherosclerosis has been clearly documented in
TAK [5, 6], and the incidence of cardiovascular events is
higher in patients with TAK than in age- and sex-
matched controls [4]. Considering the relevance of car-
diovascular events in patients’ morbidity and mortality,
it is important to identify patients at higher risk of car-
diovascular events so that appropriate prevention can be
implemented.
Increased morbidity and mortality from cardiovascular
events have been reported in other inflammatory rheum-
atic diseases such as rheumatoid arthritis (RA), ankylos-
ing spondylitis, and systemic lupus erythematosus [7–9].
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The increased risk of cardiovascular events in these dis-
eases is only partly explained by increased prevalence of
traditional cardiovascular risk factors such as age, sex,
dyslipidemia, hypertension, smoking, obesity, and dia-
betes mellitus [10]. Systemic inflammation, in addition
to traditional cardiovascular risk factors, has been sug-
gested as the main contributor to cardiovascular events
in inflammatory rheumatic diseases [10]. Indeed, there is
a well-known association between chronic inflammation
and atherosclerosis [11–13].
In patients with TAK, it is unclear whether TAK
disease-specific factors also account for accelerated ath-
erosclerosis and increased cardiovascular events, apart
from the higher prevalence of traditional cardiovascular
risk factors [2–4]. Current cardiovascular risk assess-
ment tools using traditional cardiovascular risk factors
may not reflect the actual risk of cardiovascular events
in patients with TAK, and a disease-specific risk score is
needed [4]. Although a previous study reported that in
addition to traditional cardiovascular risk factors, anemia
and low body mass index are factors independently asso-
ciated with increased cardiovascular events [14], data re-
garding TAK disease-specific factors associated with
cardiovascular events are still limited.
In this study, we aimed to identify TAK disease-
specific factors associated with the risk of cardiovascular




In this retrospective cohort study, patients diagnosed
with TAK and followed between 2006 and 2019 at two
tertiary referral hospitals were included. All patients ful-
filled the American College of Rheumatology (ACR)
1990 criteria for the classification of TAK [15]. Patients
who concurrently had other chronic inflammatory dis-
eases such as spondyloarthritis and inflammatory bowel
diseases were excluded. Patients with a history of cardio-
vascular events or chronic kidney disease prior to the
diagnosis of TAK were also excluded. Electronic medical
records of each patient were reviewed from the index
date (i.e., the date of diagnosis of TAK) to the last
follow-up date. Data regarding traditional cardiovascular
risk factors, TAK disease-specific factors, and incident
cardiovascular events in each patient were extracted.
This study was approved by the institutional review
board (IRB) of Gangnam Severance Hospital (IRB No. 3-
2019-0423). Owing to the retrospective nature of this
study, the requirement for informed consent was waived.
Covariates
Regarding traditional CV risk factors, age, sex, presence
of hypertension, use of antihypertensive drugs, systolic
and diastolic blood pressure (BP), presence of diabetes
mellitus, smoking status (current smoker or not), and
lipid profile (total cholesterol, triglycerides, high-density
lipoprotein [HDL] cholesterol, and low-density lipopro-
tein [LDL] cholesterol) at index date were evaluated.
The 2008 Framingham 10-year risk score of general car-
diovascular disease [16] was calculated based on col-
lected data. Body mass index (BMI) and hemoglobin
levels at index date were also evaluated. In regard to
TAK disease-specific factors, erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP) levels, type of vas-
cular involvement according to the Hata classification
[17], involvement of pulmonary arteries, presence of aor-
tic regurgitation, use of glucocorticoids, aspirin, and sta-
tins at index date were evaluated. The use of
glucocorticoids was categorized as none-to-low and
medium-to-high dose according to the dose received at
the index date. A glucocorticoid dose of ≤ 7.5 mg pred-
nisolone equivalent a day was considered none-to-low
dose, and a glucocorticoid dose of > 7.5 mg and ≤ 100
mg prednisolone equivalent a day was considered
medium-to-high dose [18]. The use of methotrexate
(MTX) and azathioprine (AZA) until the last follow-up
date or the date of incident cardiovascular event, which-
ever came first, was also assessed. The medication was
considered “used” if it had been received for at least 3
months.
Definition of cardiovascular events
Cardiovascular events were defined as documented epi-
sodes of coronary artery disease (angina, myocardial infarc-
tion, and revascularization procedures), cerebrovascular
events (transient ischemic attack, and stroke; both cerebral
infarction and hemorrhage), and congestive heart failure
(both compensated and decompensated) that occurred be-
tween the index date and last follow-up date, as defined in
a previous meta-analysis [19]. Shortness of breath or non-
specific ST-T change in electrocardiogram or paroxysmal
arrhythmia, respectively, was not considered as a cardio-
vascular event.
Statistical analysis
To summarize patient characteristics, continuous vari-
ables were expressed as mean ± standard deviation or
median (interquartile range) for parametric or non-
parametric variables, respectively, while categorical vari-
ables were expressed as numbers (%). The normality of
continuous variables was evaluated using the Kolmogo-
rov–Smirnov test. Characteristics of patients who did
and did not develop cardiovascular events were com-
pared. Student’s t test or Mann–Whitney U test was per-
formed for parametric or non-parametric continuous
variables, respectively, and χ2 test (or Fisher’s exact test)
was used to compare categorical variables. To estimate
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the risk of cardiovascular events according to potential
TAK disease-specific factors, multivariable Cox propor-
tional hazard regression analysis adjusted for traditional
cardiovascular risk factors (age, sex, total cholesterol, HDL
cholesterol, hypertension, diabetes mellitus, and smoking
history) [16] was performed. The proportional hazards as-
sumption was confirmed by examination of log (− log
[survival]) curves and by testing Schoenfeld partial resid-
uals; no relevant violations were found. For the interpret-
ation of drug effects, adjustment with propensity score
using inverse probability of treatment weighting (IPTW)
was performed to minimize channeling bias. A P value of
< 0.05 was considered statistically significant. All analyses
were conducted using the SPSS software (version 25.0;
IBM Corporation, Armonk, NY, USA).
Results
Incidence of cardiovascular events
A total of 207 patients with TAK who fulfilled the ACR
1990 classification criteria were included in the analysis.
The median follow-up duration was 5.6 (2.1–10.9) years.
Majority of the patients were female (174 of 207, 84.1%),
and the mean age was 39.5 ± 13.2 years (Table 1). Car-
diovascular events occurred in 41 (19.8%) patients, in
median 3.0 (1.0–6.4) years of follow-up. Of the 41 car-
diovascular events, 23 were coronary arterial events, 15
were cerebrovascular events, and 3 were congestive heart
failure. The incidence of cardiovascular events was 41
per 1383.9 person-years.
Comparison between patients who did and did not
develop cardiovascular events
Compared with patients who did not develop cardiovas-
cular events, patients who developed cardiovascular
events were older (38.5 ± 13.4 years vs. 43.6 ± 11.8 years,
p = 0.028), more commonly had diabetes mellitus (6.6%
vs. 19.5%, p = 0.029), had lower HDL cholesterol levels
(57.3 ± 17.1 mg/dl vs. 51.2 ± 15.7 mg/dl, p = 0.040), more
commonly exhibited a type V vascular involvement pat-
tern (33.1% vs. 63.4%, p < 0.001) at the index date, and
less commonly received MTX during the follow-up
(65.1% vs. 43.9%, p = 0.013) (Table 2). There was no sig-
nificant difference in sex distribution, prevalence of
hypertension, use of antihypertensive drugs, systolic and
diastolic BP, smoking status, total cholesterol, triglycer-
ides, LDL cholesterol, BMI, hemoglobin, ESR, CRP,
prevalence of pulmonary artery involvement and aortic
regurgitation, and use of glucocorticoids, aspirin, and
statins at the index date. Importantly, no significant dif-
ference in the Framingham risk score was observed be-
tween the two groups (3.9 [2.4–7.1]% vs. 5.5 [2.9–9.7]%,
p = 0.119).
Table 1 Characteristics of 207 patients with TAK
N = 207
Age, years, mean (±SD) 39.5 ± 13.2
Female sex, n (%) 174 (84.1)
Hypertension, n (%) 100 (48.3)
Use of antihypertensive drugs, n (%) 100 (48.3)
Systolic BP, mmHg, mean (±SD) 129.3 ± 16.1
Diastolic BP, mmHg, mean (±SD) 75.6 ± 12.6
Diabetes mellitus, n (%) 19 (9.2)
Smoking, n (%) 18 (8.7)
Total cholesterol, mg/dl, mean (±SD) 180.8 ± 41.0
Triglycerides, mg/dl, mean (±SD) 112.6 ± 66.4
HDL cholesterol, mg/dl, mean (±SD) 56.1 ± 17.0
LDL cholesterol, mg/dl, mean (±SD) 102.2 ± 32.7
Framingham risk score, %, median (IQR)a 4.1 (2.5–8.0)
BMI, kg/m2, mean (±SD) 22.5 ± 3.1
Hemoglobin, g/dl, mean (± SD) 12.3 ± 1.5
Anemia, n (%) 84 (40.6)
ESR, mm/h, median (IQR) 40.0 (20.0–67.0)
CRP, mg/l, median (IQR) 4.0 (1.0–22.0)







Pulmonary artery involvement, n (%) 16 (7.7)
Aortic regurgitation, n (%) 61 (29.5)
Use of glucocorticoids, n (%)
None-to-low dose 85 (41.1)
Medium-to-high dose 122 (58.9)
Use of MTX, n (%) 126 (60.9)
Use of AZA, n (%) 38 (18.4)
Use of aspirin, n (%) 123 (59.4)
Use of statins, n (%) 123 (59.4)
Cardiovascular events, n (%) 41 (19.8)
Coronary arterial events 23 (11.1)
Cerebrovascular events 15 (7.2)
Congestive heart failure 3 (1.4)
TAK Takayasu arteritis, BP blood pressure, HDL high-density lipoprotein, LDL
low-density lipoprotein, BMI body mass index, ESR erythrocyte sedimentation
rate, CRP C-reactive protein, MTX methotrexate, AZA azathioprine, SD standard
deviation, IQR interquartile range
aPatients aged < 30 years were excluded as per the formula of calculation
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Estimation of risk of cardiovascular events according to
TAK disease-specific factors
Table 3 shows the results of Cox proportional hazard re-
gression analyses estimating the risk of cardiovascular
events according to TAK disease-specific factors. In the
univariable analysis, type V vascular involvement was asso-
ciated with increased risk of cardiovascular events com-
pared with other types (unadjusted hazard ratio [HR] 2.741,
95% confidence interval [CI] 1.443–5.205, p = 0.002),
whereas the use of MTX was associated with reduced risk
of cardiovascular events (unadjusted HR 0.474, 95% CI
0.253–0.887, p = 0.020). After adjusting for traditional car-
diovascular risk factors, the observed associations persisted
(for type V vascular involvement, adjusted HR 2.852, 95%
CI 1.474–5.518, p = 0.002; for the use of MTX, adjusted HR
0.515, 95% CI 0.268–0.993, p = 0.047). Furthermore, adjust-
ment with propensity score using IPTW confirmed that
use of MTX was associated with reduced risk of
Table 2 Comparison of patient characteristics according to the development of cardiovascular events during follow-up
CV events not occurred (N = 166) CV events occurred (N = 41) P value
Age, years, mean (±SD) 38.5 ± 13.4 43.6 ± 11.8 0.028
Female sex, n (%) 138 (83.1) 36 (87.8) 0.464
Hypertension, n (%) 75 (45.2) 25 (61.0) 0.070
Use of antihypertensive drugs, n (%) 75 (45.2) 25 (61.0) 0.070
Systolic BP, mmHg, mean (± SD) 128.9 ± 15.8 130.9 ± 17.0 0.477
Diastolic BP, mmHg, mean (± SD) 75.2 ± 12.5 76.9 ± 13.2 0.439
Diabetes mellitus, n (%) 11 (6.6) 8 (19.5) 0.029
Smoking, n (%) 12 (7.2) 6 (14.6) 0.210
Total cholesterol, mg/dl, mean (± SD) 182.9 ± 40.4 172.9 ± 42.6 0.167
Triglycerides, mg/dl, mean (± SD) 108.6 ± 57.8 127.6 ± 91.1 0.209
HDL cholesterol, mg/dl, mean (± SD) 57.3 ± 17.1 51.2 ± 15.7 0.040
LDL cholesterol, mg/dl, mean (± SD) 103.8 ± 32.4 96.2 ± 33.8 0.183
Framingham risk score, %, median (IQR)a 3.9 (2.4–7.1) 5.5 (2.9–9.7) 0.119
BMI, kg/m2, mean (± SD) 22.5 ± 3.3 22.7 ± 2.7 0.702
Hemoglobin, g/dl, mean (± SD) 12.3 ± 1.5 12.3 ± 1.3 0.980
Anemia, n (%) 66 (39.8) 18 (43.9) 0.629
ESR, mm/h, median (IQR) 39.0 (20.5–68.5) 41.0 (20.0–66.3) 0.717
CRP, mg/l, median (IQR) 4.1 (1.0–23.1) 3.6 (1.0–15.2) 0.908
Type of vascular involvement, n (%)
I 42 (25.3) 6 (14.6) 0.147
IIA 19 (11.4) 4 (9.8) > 0.999
IIB 32 (19.3) 4 (9.8) 0.150
III 7 (4.2) 1 (1.6) > 0.999
IV 11 (6.6) 0 (0.0) 0.126
V 55 (33.1) 26 (63.4) < 0.001
Pulmonary artery involvement, n (%) 13 (7.8) 3 (7.3) > 0.999
Aortic regurgitation, n (%) 44 (26.5) 17 (41.5) 0.060
Use of glucocorticoids, n (%)
None-to-low dose 66 (39.8) 19 (46.3) 0.443
Medium-to-high dose 100 (60.2) 22 (53.7)
Use of MTX, n (%) 108 (65.1) 18 (43.9) 0.013
Use of AZA, n (%) 33 (19.9) 5 (12.2) 0.255
Use of aspirin, n (%) 94 (56.6) 29 (70.7) 0.100
Use of statins, n (%) 97 (58.4) 26 (63.4) 0.561
CV cardiovascular, BP blood pressure, HDL high-density lipoprotein, LDL low-density lipoprotein, BMI body mass index, ESR erythrocyte sedimentation rate, CRP C-
reactive protein, MTX methotrexate, AZA azathioprine, SD standard deviation, IQR interquartile range
aPatients aged < 30 years were excluded as per the formula of calculation
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cardiovascular events (IPTW-adjusted HR 0.401, 95% CI
0.168–0.957, p = 0.040).
Discussion
In this study, we observed that type V vascular involve-
ment was associated with increased risk of cardiovascu-
lar events, while the use of MTX was associated with
reduced risk of cardiovascular events in patients with
TAK. To our knowledge, this is the first study to exam-
ine TAK disease-specific factors associated with cardio-
vascular events.
Type V vascular involvement, which is the most exten-
sive pattern of vascular involvement [17], was associated
with approximately three times higher risk (adjusted HR
2.852) of cardiovascular events than the other types. It is
challenging to determine whether this association is at-
tributable to arterial vasculitic involvement itself or to
accelerated atherosclerosis due to chronic systemic in-
flammation. Considering that ESR and CRP were not as-
sociated with the risk of cardiovascular events in the
multivariable Cox proportional hazard regression ana-
lysis, we presume that the increased risk of cardiovascu-
lar events is more likely attributable to arterial vasculitic
involvement than to the accelerated atherosclerosis by
chronic inflammation. Indeed, ESR (37.0 [20.3–62.3]
mm/h vs. 42.0 [20.0–69.0] mm/h, p = 0.612) and CRP
(5.0 [1.0–23.0] mg/l vs. 3.1 [1.0–20.9] mg/l, p = 0.523)
levels did not differ between patients with type V and
those with other types of vascular involvement (data not
shown in results). Interestingly, a previous study re-
ported that small retinal vessel involvement in TAK may
be associated with type V vascular involvement [20].
Similar to previous findings, we also found that type V
vascular involvement may be associated with coronary
artery or cerebral artery involvement, leading to in-
creased risk of cardiovascular events. Moreover, we have
previously observed that type V was the most common
(4 of 7, 57.1%) type of vascular involvement in mortality
cases caused by cardiovascular events, supporting type V
vascular involvement as a risk factor of cardiovascular
events [21].
MTX, which is commonly administered in patients
with TAK to achieve remission or to spare glucocortic-
oid, is the cornerstone of RA treatment [22]. The benefi-
cial effect of MTX on cardiovascular events has been
reported in patients with RA: MTX was associated with
28–66% reduction in cardiovascular events [23–25].
Similar to the observations in patients with RA, we also
found that the use of MTX was associated with approxi-
mately 60% reduced risk (IPTW-adjusted HR 0.401) of
cardiovascular events in patients with TAK. Given the
established association between chronic inflammation
and atherosclerosis [11–13], the association between the
use of MTX and reduced risk of cardiovascular events
might be contributed by reduced disease activity (i.e., in-
flammation). However, the use of AZA, another
Table 3 Risk of cardiovascular disease according to TAK disease-specific factors
Univariable analysis Multivariable analysisa
Unadjusted HR (95% CI) P value Adjusted HR (95% CI) P value
BMI 1.031 (0.926–1.146) 0.579 0.905 (0.796–1.029) 0.129
Anemia 0.880 (0.468–1.654) 0.691 0.924 (0.464–1.838) 0.821
ESR 1.001 (0.991–1.011) 0.878 0.996 (0.985–1.008) 0.551
CRP 0.995 (0.986–1.005) 0.326 0.993 (0.982–1.003) 0.183
Vascular involvement type
Types other than V 1.000 (reference) 1.000 (reference)
Type V 2.741 (1.443–5.205) 0.002 2.852 (1.474–5.518) 0.002
Pulmonary artery involvement 1.011 (0.311–3.288) 0.985 0.717 (0.193–2.655) 0.618
Aortic regurgitation 1.341 (0.703–2.558) 0.373 1.024 (0.505–2.077) 0.947
Use of glucocorticoids
None-to-low dose 1.000 (reference) 1.000 (reference)
Medium-to-high dose 0.780 (0.414–1.471) 0.443 1.030 (0.523–2.030) 0.932
Use of MTX 0.474 (0.253–0.887) 0.020 0.515 (0.268–0.993) 0.047
Use of AZA 0.592 (0.231–1.513) 0.273 0.768 (0.278–2.122) 0.611
Use of aspirin 1.763 (0.880–3.532) 0.110 1.426 (0.695–2.925) 0.333
Use of statins 1.220 (0.640–2.327) 0.546 0.789 (0.391–1.592) 0.508
TAK Takayasu arteritis, HR hazard ratio, CI confidence interval, BMI body mass index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, MTX methotrexate,
AZA azathioprine
aAdjusted for traditional cardiovascular risk factors (age, sex, systolic BP, use of antihypertensive drugs, total cholesterol, HDL cholesterol, diabetes mellitus, and
smoking status)
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medication effectively used for controlling the disease
activity of TAK [26], was not associated with reduced
risk of cardiovascular events in this study. In addition to
the indirect effects mediated by reduction in disease ac-
tivity, MTX exerts direct cardioprotective properties by
promoting cholesterol efflux, improving endothelial
function and reducing oxidative stress [27–30]. These
cardioprotective effects might explain why MTX, but
not AZA, was associated with reduced risk of cardiovas-
cular events in our study.
A previous study reported that the use of aspirin
reduced the risk of acute ischemic events, while the
use of statins was not associated with the risk of car-
diovascular events in patients with TAK [31]. Simi-
larly, we found no significant association between the
use of statins and risk of cardiovascular events in this
study. However, we also did not observe a significant
association between the use of aspirin and risk of car-
diovascular events. The effect of aspirin seems contro-
versial, with another study reporting no significant
effect of aspirin on the risk of cardiovascular events
[4], consistent with our present study. Aspirin and
statins are commonly used for cardioprotection;
therefore, their effects are likely to be confounded by
indication. Prospective studies are needed to clearly
assess the cardioprotective effect of these medications
in patients with TAK.
Contrary to a report supporting the association of
anemia and low BMI with increased cardiovascular
events in patients with TAK [14], another study refuted
such an association [4]. In the present study, we also did
not find a significant association between these factors
and cardiovascular events. The significance of anemia
and low BMI as risk factors for cardiovascular events in
patients with TAK remains unclear.
Interestingly, the Framingham risk score at the index
date did not differ between patients who developed car-
diovascular events and those who did not. This suggests
that assessment of cardiovascular risk using the current
assessment tools is not as accurate in patients with TAK
as it is in the general population. Additional consider-
ation of disease-specific factors, such as type V vascular
involvement and the use of MTX as identified in this
study, may lead to better cardiovascular risk assessment
in patients with TAK.
Our study had several limitations. First, this was a
retrospective study. Although we found some signifi-
cant associations between TAK disease-specific factors
and cardiovascular events, the causal relationship
could not be fully addressed. Second, CRP levels were
relatively low in the total population compared with
other studies. This may have led to an underestima-
tion of the association between CRP levels and car-
diovascular events.
Conclusion
In conclusion, we showed that type V vascular involve-
ment was associated with increased risk of cardiovascu-
lar events, whereas the use of MTX was associated with
reduced risk of cardiovascular events, independent of
traditional cardiovascular risk factors. In addition to the
traditional cardiovascular risk factors, these TAK
disease-specific factors may aid in the estimation of a
more accurate disease-specific risk score for cardiovas-
cular events in patients with TAK.
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